Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FSCD1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $52,887
Award facts
- Contract value 100% obligated
- $52,886.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $52,886.58 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cabometyx 40 mg tablets (30-count units). The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for the Department of Defense's military healthcare operations, with this delivery order representing one of numerous orders issued under the broader $30.3 billion PPV-G GEN V acquisition strategy designed to ensure a reliable supply of pharmaceuticals to military medical facilities worldwide. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with Cabometyx—an oncology treatment—reflecting the contractor's capability to supply specialized pharmaceutical products essential to DoD healthcare operations. As a woman-owned small business with demonstrated federal contracting performance, DMS Pharmaceutical Group leverages its established presence in the pharmaceutical supply chain to fulfill the diverse medical supply requirements of the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FSCD1?
SPE2DR26FSCD1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FSCD1 worth?
The government has obligated $52,887 on SPE2DR26FSCD1.
Is contract SPE2DR26FSCD1 an order under another contract?
Yes. SPE2DR26FSCD1 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCD1 competed?
The extent of competition for SPE2DR26FSCD1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award